Investigation of an efficacy of eplerenone combined therapy for hypertensive patients with chronic kidney disease that enough hypotensive effect are not obtained with an angiotensin receptor blocker

Trial Profile

Investigation of an efficacy of eplerenone combined therapy for hypertensive patients with chronic kidney disease that enough hypotensive effect are not obtained with an angiotensin receptor blocker

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Aug 2017

At a glance

  • Drugs Eplerenone (Primary) ; Hydrochlorothiazide; Trichlormethiazide
  • Indications Hypertension; Renal failure
  • Focus Therapeutic Use
  • Acronyms OWASE
  • Most Recent Events

    • 28 Aug 2017 Primary endpoint (Mean percent change in UACR) has not been met, according to the results published in the Journal of Clinical Hypertension (Greenwich).
    • 28 Aug 2017 Results published in the Journal of Clinical Hypertension (Greenwich)
    • 29 Sep 2016 Results of subanalysis (n=68) presented at the 26th Scientific Meeting of the International Society of Hypertension
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top